BRIVARACETAM

Information current as at: 1 May 2025

The processes outlined in the MSW are not applicable to this medicine. Please contact pbs@health.gov.au or 1800 020 613 for further information.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Briviact®
Pharmaceutical company:
UCB Australia Pty Ltd
Condition/indication:
(therapeutic use)
  • Epilepsy
PBAC Submission type:
Change to listing (Major)
Comment:
--
Related medicines:
--

Progress Details

Submission received for:
November 2019 PBAC meeting
Opportunity for consumer comment:
Open 28/08/2019 and close 09/10/2019 (see PBS Website)
PBAC meeting:
Held on 06/11/2019
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Not Applicable
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable

Case ID: a060

Page last updated: 31 October 2024

v.9.18